Improving care for CLL patients

Adaptive Biotechnologies received FDA clearance for the clonoSEQ® Assay, used to assess the minimal residual disease in a chronic lymphocytic leukemia patient’s blood. Previously, the test was only available using a patient’s bone marrow. This advancement will help improve the ability to know how many cancer cells remain during and following treatment, providing patients and healthcare providers with a more convenient and less intrusive option to detect and monitor disease.

READ MORE at LinkedIn »